IL272262A - Analogues of 2,1-dihydro-H3-pyrazolo[4,3-D]pyrimidine-3-one - Google Patents
Analogues of 2,1-dihydro-H3-pyrazolo[4,3-D]pyrimidine-3-oneInfo
- Publication number
- IL272262A IL272262A IL272262A IL27226220A IL272262A IL 272262 A IL272262 A IL 272262A IL 272262 A IL272262 A IL 272262A IL 27226220 A IL27226220 A IL 27226220A IL 272262 A IL272262 A IL 272262A
- Authority
- IL
- Israel
- Prior art keywords
- pyrazolo
- pyrimidin
- dihydro
- analogs
- Prior art date
Links
- JTNQNHQPENYUGB-UHFFFAOYSA-N 1,2-dihydropyrazolo[3,4-d]pyrimidin-3-one Chemical class C1=NC=C2C(O)=NNC2=N1 JTNQNHQPENYUGB-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762539734P | 2017-08-01 | 2017-08-01 | |
| PCT/US2018/044580 WO2019028008A1 (en) | 2017-08-01 | 2018-07-31 | 1,2-DIHYDRO-3H-PYRAZOLO [3,4-D] PYRIMIDIN-3-ONE ANALOGUES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL272262A true IL272262A (en) | 2020-03-31 |
Family
ID=65233095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL272262A IL272262A (en) | 2017-08-01 | 2020-01-26 | Analogues of 2,1-dihydro-H3-pyrazolo[4,3-D]pyrimidine-3-one |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11124518B2 (enExample) |
| EP (1) | EP3661918B1 (enExample) |
| JP (1) | JP7203816B2 (enExample) |
| KR (1) | KR20200034781A (enExample) |
| CN (1) | CN111094253B (enExample) |
| AR (1) | AR112774A1 (enExample) |
| AU (1) | AU2018312448B2 (enExample) |
| BR (1) | BR112020002104A2 (enExample) |
| CA (1) | CA3071405A1 (enExample) |
| ES (1) | ES2980537T3 (enExample) |
| IL (1) | IL272262A (enExample) |
| MX (1) | MX2020001235A (enExample) |
| RU (1) | RU2020105058A (enExample) |
| SG (1) | SG11202000789WA (enExample) |
| TW (1) | TW201910335A (enExample) |
| WO (1) | WO2019028008A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018347307A1 (en) | 2017-10-09 | 2020-04-23 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| EP3694861A4 (en) * | 2017-10-09 | 2021-05-19 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
| CA3088997A1 (en) * | 2018-02-28 | 2019-09-06 | The Regents Of The University Of Colorado, A Body Corporate | Wee1 kinase inhibitors and methods of treating cancer using the same |
| RS66798B1 (sr) * | 2018-03-09 | 2025-06-30 | Recurium Ip Holdings Llc | Supstituisani 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-oni |
| CN110872296B (zh) * | 2018-08-31 | 2023-05-23 | 上海弘翊生物科技有限公司 | 一种二氢异吲哚-1H-吡唑并[3,4-d]嘧啶酮化合物、其制备方法和应用 |
| EP3952876A4 (en) * | 2019-04-09 | 2023-04-19 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND THEIR USES |
| WO2020210380A1 (en) * | 2019-04-09 | 2020-10-15 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
| CN113939296A (zh) * | 2019-04-09 | 2022-01-14 | 诺维逊生物股份有限公司 | 杂环化合物及其用途 |
| WO2020210320A1 (en) * | 2019-04-11 | 2020-10-15 | Recurium Ip Holdings, Llc | Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
| KR20220042127A (ko) | 2019-06-28 | 2022-04-04 | 상하이 파마슈티컬스 홀딩 컴퍼니 리미티드 | 피라졸로피리미딘 화합물, 그의 제조 방법 및 그의 응용 |
| CN112142748B (zh) * | 2019-06-28 | 2023-07-04 | 上海医药集团股份有限公司 | 一种吡唑酮并嘧啶类化合物、其制备方法及应用 |
| CN112442049A (zh) * | 2019-09-03 | 2021-03-05 | 微境生物医药科技(上海)有限公司 | 作为Wee1抑制剂的嘧啶衍生物 |
| KR20220103748A (ko) | 2019-11-15 | 2022-07-22 | 리커리엄 아이피 홀딩스, 엘엘씨 | 3차 알코올의 키랄 합성 |
| EP4069235A4 (en) * | 2019-12-20 | 2024-01-10 | Recurium IP Holdings, LLC | ASSOCIATIONS |
| NZ793883A (en) * | 2020-05-15 | 2025-11-28 | Recurium Ip Holdings Llc | Mono- and combination therapies |
| WO2021254389A1 (zh) * | 2020-06-17 | 2021-12-23 | 微境生物医药科技(上海)有限公司 | 作为Wee-1抑制剂的吡唑并[3，4-d]嘧啶-3-酮衍生物 |
| CN114805357B (zh) * | 2021-01-21 | 2023-12-19 | 四川大学 | 一种靶向setdb1-ttd的小分子抑制剂及其制药用途 |
| KR20240004539A (ko) * | 2021-04-30 | 2024-01-11 | 위겐 바이오메더슨 테크널러지 (상하이) 컴퍼니 리미티드 | Wee-1 억제제로서의 축합 고리 화합물, 그를 위한 제조 방법 및 그의 용도 |
| CN117751122A (zh) * | 2021-08-11 | 2024-03-22 | 微境生物医药科技(上海)有限公司 | 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物 |
| CN117940430B (zh) * | 2021-09-22 | 2025-10-31 | 微境生物医药科技(上海)有限公司 | 作为Wee-1抑制剂的1,2-二氢-3H-吡唑[3,4-d]嘧啶-3-酮化合物 |
| WO2023166080A1 (en) | 2022-03-01 | 2023-09-07 | Step Pharma S.A.S. | Combination treatments comprising a ctps1 inhibitor and a wee1 inhibitor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2594425A1 (en) * | 2005-01-14 | 2006-07-20 | Janssen Pharmaceutica N.V. | 5-membered annelated heterocyclic pyrimidines as kinase inhibitors |
| AR060635A1 (es) * | 2006-04-27 | 2008-07-02 | Banyu Pharma Co Ltd | Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer |
| WO2009054332A1 (ja) * | 2007-10-23 | 2009-04-30 | Banyu Pharmaceutical Co., Ltd. | ピリドン置換ジヒドロピラゾロピリミジノン誘導体 |
| RS58956B1 (sr) * | 2012-09-10 | 2019-08-30 | Principia Biopharma Inc | Jedinjenja pirazolopirimidina kao inhibitori kinaze |
| GB201612092D0 (en) * | 2016-07-12 | 2016-08-24 | Almac Discovery Ltd | Pharmaceutical compounds |
-
2018
- 2018-07-31 TW TW107126578A patent/TW201910335A/zh unknown
- 2018-07-31 KR KR1020207005636A patent/KR20200034781A/ko not_active Ceased
- 2018-07-31 BR BR112020002104-0A patent/BR112020002104A2/pt not_active Application Discontinuation
- 2018-07-31 JP JP2020505356A patent/JP7203816B2/ja active Active
- 2018-07-31 ES ES18842344T patent/ES2980537T3/es active Active
- 2018-07-31 AU AU2018312448A patent/AU2018312448B2/en not_active Ceased
- 2018-07-31 CA CA3071405A patent/CA3071405A1/en active Pending
- 2018-07-31 RU RU2020105058A patent/RU2020105058A/ru unknown
- 2018-07-31 US US16/635,348 patent/US11124518B2/en active Active
- 2018-07-31 WO PCT/US2018/044580 patent/WO2019028008A1/en not_active Ceased
- 2018-07-31 CN CN201880059242.4A patent/CN111094253B/zh active Active
- 2018-07-31 MX MX2020001235A patent/MX2020001235A/es unknown
- 2018-07-31 EP EP18842344.6A patent/EP3661918B1/en active Active
- 2018-07-31 SG SG11202000789WA patent/SG11202000789WA/en unknown
- 2018-08-01 AR ARP180102185A patent/AR112774A1/es not_active Application Discontinuation
-
2020
- 2020-01-26 IL IL272262A patent/IL272262A/en unknown
-
2021
- 2021-06-15 US US17/304,154 patent/US20210317124A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3661918B1 (en) | 2024-05-08 |
| WO2019028008A1 (en) | 2019-02-07 |
| RU2020105058A3 (enExample) | 2021-11-17 |
| JP7203816B2 (ja) | 2023-01-13 |
| RU2020105058A (ru) | 2021-09-02 |
| AU2018312448B2 (en) | 2022-09-15 |
| AU2018312448A1 (en) | 2020-02-13 |
| ES2980537T3 (es) | 2024-10-01 |
| CA3071405A1 (en) | 2019-02-07 |
| TW201910335A (zh) | 2019-03-16 |
| MX2020001235A (es) | 2020-07-20 |
| AR112774A1 (es) | 2019-12-11 |
| EP3661918A1 (en) | 2020-06-10 |
| CN111094253A (zh) | 2020-05-01 |
| US20210317124A1 (en) | 2021-10-14 |
| EP3661918C0 (en) | 2024-05-08 |
| CN111094253B (zh) | 2023-08-29 |
| US11124518B2 (en) | 2021-09-21 |
| SG11202000789WA (en) | 2020-02-27 |
| US20200157112A1 (en) | 2020-05-21 |
| KR20200034781A (ko) | 2020-03-31 |
| BR112020002104A2 (pt) | 2020-08-04 |
| EP3661918A4 (en) | 2021-05-12 |
| JP2020529993A (ja) | 2020-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL272262A (en) | Analogues of 2,1-dihydro-H3-pyrazolo[4,3-D]pyrimidine-3-one | |
| IL276802B1 (en) | Transduced 2,1-dihydro-3h-pyrazolo[4,3-d]pyrimidine-3-ones | |
| IL253284A0 (en) | History of 4h-pyrrolo[2,3-c]pyridine-4-one | |
| IL250823A0 (en) | A new derivative of 6,5-dihydro-h4-benzo[b]thiano-[3,2-d]azepine | |
| SG11201801365YA (en) | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | |
| GB2589796B (en) | Long-offset acquisition | |
| IL248277A0 (en) | Compounds of the type: 2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl-1,3-thiazol-4-yl amides | |
| IL254167A0 (en) | Combinations containing modified 3,2-dihydroimidazo[2,1-c]quinazoline | |
| IL257757A (en) | Substituted 1,2-dihydro-3h-pyrrolo[1,2-c]imidazol-3-one antibacterial compounds | |
| IL273387A (en) | Thylanstatin analogs | |
| IL257413A (en) | Substituted 1,2-dihydro-3h pyrrolo[1,2-c]imidazol-3 one antibacterials | |
| CA185995S (en) | One-piece garment | |
| SG11201803584RA (en) | 1,4-dicarbonyl-piperidyl derivatives | |
| GB201522532D0 (en) | Novel pyrrolo[3,2-c]pyridine-6-amino derivatives | |
| CA185994S (en) | One-piece garment | |
| CA185993S (en) | One-piece garment | |
| IL258217A (en) | 2,3,4,5 tetrahydropyridin-6-amine derivatives | |
| CA185991S (en) | One-piece garment | |
| CA185992S (en) | One-piece garment | |
| HK40027677A (en) | 1, 2-dihydro-3h-pyrazolo [3, 4-d]pyrimidin-3-one analogs | |
| HK40033093A (en) | Thailanstatin analogs | |
| ZA201801639B (en) | Substituted 1,2-dihydro-3h pyrrolo[1,2-c]imidazol-3 one antibacterials | |
| PH32018000939S1 (en) | Coaster | |
| HUP1700542A2 (en) | Nucleosides modified by 5'-linker | |
| GB201718386D0 (en) | The brain project |